Allena Pharmaceuticals Inc.
| NASDAQ: ALNA | Healthcare / Biotechnology / USA |
| 1.08 | -0.0300 | -2.70% | Vol 660.51K | 1Y Perf -31.96% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 1.05 | ASK | 1.12 | ||
| Open | 1.10 | Previous Close | 1.11 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 7.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 548.15 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Market Cap | 61.49M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 2.53 | Earnings Date | 12th May 2021 |
Today's Price Range 1.021.13 | 52W Range 1.023.39 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -10.00% | ||
| 1 Month | -34.94% | ||
| 3 Months | -33.74% | ||
| 6 Months | -19.40% | ||
| 1 Year | -31.96% | ||
| 3 Years | -92.22% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -220.47 | |||
ROE last 12 Months | -159.08 | |||
ROA (5Y Avg) | -90.92 | |||
ROA last 12 Months | -86.36 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -106.05 | |||
Return on invested Capital Q | -33.46 | |||
Return on invested Capital Y | -108.06 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 2.82 | ||||
| - | ||||
| - | ||||
| -3.10 | ||||
| -0.87 | ||||
| 2.82 | ||||
| 0.40 | ||||
| 39.19M | ||||
| Forward PE | -1.23 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.70 | ||||
| 6.10 | ||||
| 0.31 | ||||
| 0.47 | ||||
| - | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.18 | -0.24 | -33.33 |
| Q03 2020 | -0.21 | -0.22 | -4.76 |
| Q02 2020 | -0.29 | -0.26 | 10.34 |
| Q01 2020 | -0.43 | -0.31 | 27.91 |
| Q04 2019 | -0.58 | -0.44 | 24.14 |
| Q03 2019 | -0.48 | -0.57 | -18.75 |
| Q02 2019 | -0.55 | -0.54 | 1.82 |
| Q01 2019 | -0.49 | -0.55 | -12.24 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.20 | -11.11 | Negative |
| 6/2021 QR | -0.19 | 0.00 | - |
| 12/2021 FY | -0.87 | -4.82 | Negative |
| 12/2022 FY | -0.91 | 2.15 | Positive |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.20 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 660.51K |
| Shares Outstanding | 56.94M |
| Trades Count | 1.79K |
| Dollar Volume | 2.64M |
| Avg. Volume | 2.03M |
| Avg. Weekly Volume | 924.79K |
| Avg. Monthly Volume | 721.70K |
| Avg. Quarterly Volume | 2.12M |
Allena Pharmaceuticals Inc. (NASDAQ: ALNA) stock closed at 1.08 per share at the end of the most recent trading day (a -2.7% change compared to the prior day closing price) with a volume of 664.24K shares and market capitalization of 61.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Allena Pharmaceuticals Inc. CEO is Louis Brenner.
The one-year performance of Allena Pharmaceuticals Inc. stock is -31.96%, while year-to-date (YTD) performance is -15.63%. ALNA stock has a five-year performance of %. Its 52-week range is between 1.02 and 3.39, which gives ALNA stock a 52-week price range ratio of 2.53%
Allena Pharmaceuticals Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 2.82, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -86.36%, a ROC of -106.05% and a ROE of -159.08%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allena Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Allena Pharmaceuticals Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Allena Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7, which is +548.15% compared to the current price. The earnings rating for Allena Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allena Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.36, ATR14 : 0.15, CCI20 : -150.55, Chaikin Money Flow : -0.11, MACD : -0.17, Money Flow Index : 24.11, ROC : -20.14, RSI : 32.52, STOCH (14,3) : 15.38, STOCH RSI : 0.00, UO : 46.03, Williams %R : -84.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allena Pharmaceuticals Inc. in the last 12-months were: Edward Wholihan (Option Excercise at a value of $0), Edward Wholihan (Sold 68 550 shares of value $93 228 ), Louis Brenner (Option Excercise at a value of $0), Louis Brenner (Sold 103 116 shares of value $140 238 )
Allena Pharmaceuticals Inc.
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
CEO: Louis Brenner
Telephone: +1 617 467-4577
Address: One Newton Executive Park, Newton 02462, MA, US
Number of employees: 22
